e-Drug3D

1927

TALAZOPARIB

INN
TALAZOPARIB

cas 1207456-01-6

CLASS

ANTINEOPLASTIC
INHIBITOR OF POLYADENOSINE 5’-DIPHOSPHORIBOSE POLYMERASE (PARP) PARP1 AND PARP2

ROUTE (list)

ORAL

ATC code

L01XK04

PK parameters

Tmax 1.5 HOUR
VD 420 LITER
Cl 6.45 LITER / HOUR
PPB 74 PERCENT
t1/2 90 HOUR

Target

TARGET POLYADENOSINE 5-DIPHOSPHORIBOSE POLYMERASE (PARP)

PDB
4UND (HUMAN ARTD1 (PARP1))

Ligand code = 2YQ (link to the list of PDB complexes)

Download experimental 3D coordinates of 2YQ with added hydrogens

DrugCentral

Poly ADP-ribose polymerase 1 UNIPROT P09874 PARP1

Poly ADP-ribose polymerase 2 UNIPROT Q9UGN5 PARP2

Download SDF file

3H-Pyrido[4,3,2-de]phthalazin-3-one, 5-fluoro-8-(4-fluorophenyl)-2,7,8,9-tetrahydro-9-(1-methyl-1H-1,2,4-triazol-5-yl)-, (8S,9R)-

Formula:
C19H14F2N6O

Calculated chemical properties:

MW 380.36
NB_atoms 28
XLogP 2.63
PSA 83.098
NB_HD 2
NB_HA 7
fsp3 0.16
Lipinski(0=no;1=yes) 1

FDA
NDA 211651 (label) INN (TALAZOPARIB TOSYLATE) TALZENNA (PFIZER) APPROVAL= AP YEAR= 2018 NEWMOLECULARENTITY DISCONTINUED
NDA 217439 (label) INN (TALAZOPARIB TOSYLATE) TALZENNA (PFIZER) APPROVAL= AP YEAR= 2024